Eye Health News and Research

Latest Eye Health News and Research

UPMC Health Plan collaboration launches pediatric weight management program

A unique collaboration between UPMC Health Plan, Children's Community Pediatrics (CCP), and Children's Hospital of Pittsburgh of UPMC is utilizing a multidisciplinary team approach in the setting of the pediatrician's office to provide practical weight management strategies for children who are obese or overweight.

8 Jun 2010

Optomap Retinal Exam allows patients take complete look at eyes

Have you been putting off a trip to the optometrist because you dread getting your eyes dilated? While your doctor has said that dilation is the most important part of your eye exam, the discomfort, blurry vision and silly sunglasses associated with the eye drops are enough to make you put off scheduling a regular appointment. Now thanks to new state-of-the-art equipment, there are no more excuses for putting off your appointment.

8 Jun 2010

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened Investigational New Drug application (IND) with the United States Food and Drug Administration (US FDA). The IND is for Can-Fite's lead compound, CF101, for the treatment of patients with psoriasis. This is the third US IND for CF101, and the fourth for Can-Fite.

8 Jun 2010

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that in collaboration with OXiGENE, Professor Gordon Rustin and colleagues from the Mount Vernon Cancer Research Centre, UK and other institutions in the United Kingdom, reported positive final data from an investigator-sponsored Phase 1 study of OXi4503 in patients with solid tumors.

7 Jun 2010

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.

7 Jun 2010

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Cancer diagnostics company Biomoda, Inc. has been granted a Mexican patent for its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.

7 Jun 2010

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.

7 Jun 2010

OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

Microplasmin exhibits potential to cure 50% of patients with macular hole

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that further data from the first successful Phase III trial with microplasmin (TG-MV-006) for the non-surgical treatment of vitreomacular adhesion (VMA) were presented at the World Ophthalmology Congress by Dr. Matthew Benz, MD (The Methodist Hospital, Houston, Texas, U.S.)

7 Jun 2010

Media increases effectiveness of direct-to-patient marketing approaches

All too often, study sponsors provide research sites with an advertising budget to promote their clinical trial to patients, and yet the majority of research sites require support or guidance on where and when to invest these advertising dollars. This support comes from trained and experienced advertising professionals who are experts in knowing the best way to maximize advertising budgets, and optimize the return on advertising investment.

5 Jun 2010

Eye test to detect cattle infected with Mad Cow Disease

The eyes may or may not be windows to the soul, as the old adage goes, but scientists are reporting evidence that a peek into the eyes of cattle may become the basis for a long-sought test to detect infection with the agent that causes Mad Cow Disease. That test could help prevent the disease from spreading in the food supply. A study on using the tell-tale glow given off by eyes infected with the Mad Cow agent appears in ACS' semi-monthly journal Analytical Chemistry.

5 Jun 2010

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

A recent retrospective study by four Michigan physicians shows strong evidence that symptoms of headache, dizziness and anxiety in some patients with traumatic brain injury potentially could be alleviated or even eliminated with specialized eyeglass lenses containing prisms.

5 Jun 2010

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo Pharmaceuticals, Inc. today confirmed that its partner, R-Tech Ueno, Ltd. reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings.

5 Jun 2010

A sense of humor keeps people healthy

A sense of humor helps to keep people healthy and increases their chances of reaching retirement age. But after the age of 70, the health benefits of humor decrease, researchers at the Norwegian University of Science and Technology (NTNU) have found.

4 Jun 2010

Optomap Retinal Exam: A substitute for eye dilation

4 Jun 2010

Students develop innovative optical radar system to help blind people maneuver around obstacles

Ben-Gurion University of the Negev students have developed an innovative optical radar system that helps blind people maneuver around obstacles. The radar system incorporates a computer, two video cameras and a scanning light source to warn the blind of obstacles with audible alerts. The system detects obstacles -- even those overhead -- by scanning the depth of its surroundings, taken from two different angles - similar to that of the human eye.

4 Jun 2010

R-Tech Ueno announces completion of Phase II clinical study of UF-021 for retinitis pigmentosa

We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.

4 Jun 2010

Research may yield new urine test to diagnose autism

Children with autism have a different chemical fingerprint in their urine than non-autistic children, according to new research published tomorrow in the print edition of the Journal of Proteome Research.

3 Jun 2010

Ocutec receives further equity investment of £500K from existing investors

Ocutec Ltd, the Lanarkshire-based medical devices company, today announced that it had received a further equity investment of £500K from existing investors Discovery Investment Fund Limited, Chimaerabio, Scottish Enterprise Co-investment Fund and company founders.

3 Jun 2010

Eye Health News and Research

Latest Eye Health News and Research

UPMC Health Plan collaboration launches pediatric weight management program

Optomap Retinal Exam allows patients take complete look at eyes

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

Microplasmin exhibits potential to cure 50% of patients with macular hole

Media increases effectiveness of direct-to-patient marketing approaches

Eye test to detect cattle infected with Mad Cow Disease

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

A sense of humor keeps people healthy

Optomap Retinal Exam: A substitute for eye dilation

Students develop innovative optical radar system to help blind people maneuver around obstacles

R-Tech Ueno announces completion of Phase II clinical study of UF-021 for retinitis pigmentosa

Research may yield new urine test to diagnose autism

Ocutec receives further equity investment of £500K from existing investors

Genetics & Genomics - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in